Consensus interpretation on "Expert consensus on clinical application of tirofiban in atherosclerotic cerebrovascular disease"

Abstract

Platelet glycoprotein (GP) Ⅱ b/Ⅲ a receptor is the final common pathway of platelet aggregation and thrombosis, which can specifically and rapidly inhibit platelet aggregation. In recent years, more and more evidences support that tirofiban, a GP Ⅱ b/Ⅲ a receptor antagonist, can be used as a treatment option for thromboembolic diseases, but its application experience in clinical practice is still relatively insufficient. In order to apply tirofiban more reasonably and normatively in clinical practice, the Chinese Stroke Society organized a writing committee of well ⁃ known experts in the field of neurological intervention in China, and wrote the consensus of experts on the clinical application of tirofiban in atherosclerotic cerebrovascular diseases. It provides clinical experience and guidance for the application of tirofiban in the field of cerebrovascular disease, and guarantees the safe and effective use of drugs in medical behaviors.DOI：10.3969/j.issn.1672⁃6731.2020.05.003